0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Coagulation Factor VIII Market Research Report 2026
Published Date: 2026-02-11
|
Report Code: QYRE-Auto-28D484
Home | Market Reports | Health| Pharmacy
Global Human Coagulation Factor VIII Market Insights and Forecast to 2028
BUY CHAPTERS

Global Human Coagulation Factor VIII Market Research Report 2026

Code: QYRE-Auto-28D484
Report
2026-02-11
Pages:130
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Human Coagulation Factor VIII Market Size

The global Human Coagulation Factor VIII market was valued at US$ 12200 million in 2025 and is anticipated to reach US$ 18610 million by 2032, at a CAGR of 6.3% from 2026 to 2032.

Human Coagulation Factor VIII Market

Human Coagulation Factor VIII Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Human Coagulation Factor VIII competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
Market Drivers:
The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.
Market Challenges:
Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.
This report delivers a comprehensive overview of the global Human Coagulation Factor VIII market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Human Coagulation Factor VIII. The Human Coagulation Factor VIII market size, estimates, and forecasts are provided in terms of sales volume (K Bottles) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Human Coagulation Factor VIII market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Human Coagulation Factor VIII manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Human Coagulation Factor VIII Market Report

Report Metric Details
Report Name Human Coagulation Factor VIII Market
Accounted market size in 2025 US$ 12200 in million
Forecasted market size in 2032 US$ 18610 million
CAGR 6.3%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Recombinant Factor VIII
  • Plasma-derived Factor VIII
by Application
  • Hemophilia A
  • Spontanous / Trauma
  • Surgical
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Takeda, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, SinoCellTech, Taibang Bio, Huarun Boya, Shuanglin Bio, Yuandashuyang, Weiguang Bio
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Human Coagulation Factor VIII manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Human Coagulation Factor VIII sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Human Coagulation Factor VIII Market growing?

Ans: The Human Coagulation Factor VIII Market witnessing a CAGR of 6.3% during the forecast period 2026-2032.

What is the Human Coagulation Factor VIII Market size in 2032?

Ans: The Human Coagulation Factor VIII Market size in 2032 will be US$ 18610 million.

Who are the main players in the Human Coagulation Factor VIII Market report?

Ans: The main players in the Human Coagulation Factor VIII Market are Takeda, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, SinoCellTech, Taibang Bio, Huarun Boya, Shuanglin Bio, Yuandashuyang, Weiguang Bio

What are the Application segmentation covered in the Human Coagulation Factor VIII Market report?

Ans: The Applications covered in the Human Coagulation Factor VIII Market report are Hemophilia A, Spontanous / Trauma, Surgical, Other

What are the Type segmentation covered in the Human Coagulation Factor VIII Market report?

Ans: The Types covered in the Human Coagulation Factor VIII Market report are Recombinant Factor VIII, Plasma-derived Factor VIII

1 Human Coagulation Factor VIII Market Overview
1.1 Product Definition
1.2 Human Coagulation Factor VIII by Type
1.2.1 Global Human Coagulation Factor VIII Market Value by Type: 2025 vs 2032
1.2.2 Recombinant Factor VIII
1.2.3 Plasma-derived Factor VIII
1.3 Human Coagulation Factor VIII by Application
1.3.1 Global Human Coagulation Factor VIII Market Value by Application: 2025 vs 2032
1.3.2 Hemophilia A
1.3.3 Spontanous / Trauma
1.3.4 Surgical
1.3.5 Other
1.4 Global Human Coagulation Factor VIII Market Size Estimates and Forecasts
1.4.1 Global Human Coagulation Factor VIII Revenue 2021–2032
1.4.2 Global Human Coagulation Factor VIII Sales 2021–2032
1.4.3 Global Human Coagulation Factor VIII Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Human Coagulation Factor VIII Market Competition by Manufacturers
2.1 Global Human Coagulation Factor VIII Sales Market Share by Manufacturers (2021–2026)
2.2 Global Human Coagulation Factor VIII Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Human Coagulation Factor VIII Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Human Coagulation Factor VIII, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Human Coagulation Factor VIII, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Human Coagulation Factor VIII, Product Types and Applications
2.7 Global Key Manufacturers of Human Coagulation Factor VIII, Date of Entry into the Industry
2.8 Global Human Coagulation Factor VIII Market Competitive Situation and Trends
2.8.1 Global Human Coagulation Factor VIII Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Human Coagulation Factor VIII Players Market Share by Revenue
2.8.3 Global Human Coagulation Factor VIII Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Coagulation Factor VIII Market Scenario by Region
3.1 Global Human Coagulation Factor VIII Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Human Coagulation Factor VIII Sales by Region: 2021–2032
3.2.1 Global Human Coagulation Factor VIII Sales by Region: 2021–2026
3.2.2 Global Human Coagulation Factor VIII Sales by Region: 2027–2032
3.3 Global Human Coagulation Factor VIII Revenue by Region: 2021–2032
3.3.1 Global Human Coagulation Factor VIII Revenue by Region: 2021–2026
3.3.2 Global Human Coagulation Factor VIII Revenue by Region: 2027–2032
3.4 North America Human Coagulation Factor VIII Market Facts & Figures by Country
3.4.1 North America Human Coagulation Factor VIII Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Human Coagulation Factor VIII Sales by Country (2021–2032)
3.4.3 North America Human Coagulation Factor VIII Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Coagulation Factor VIII Market Facts & Figures by Country
3.5.1 Europe Human Coagulation Factor VIII Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Human Coagulation Factor VIII Sales by Country (2021–2032)
3.5.3 Europe Human Coagulation Factor VIII Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Coagulation Factor VIII Market Facts & Figures by Region
3.6.1 Asia Pacific Human Coagulation Factor VIII Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Human Coagulation Factor VIII Sales by Region (2021–2032)
3.6.3 Asia Pacific Human Coagulation Factor VIII Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Coagulation Factor VIII Market Facts & Figures by Country
3.7.1 Latin America Human Coagulation Factor VIII Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Human Coagulation Factor VIII Sales by Country (2021–2032)
3.7.3 Latin America Human Coagulation Factor VIII Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Coagulation Factor VIII Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Coagulation Factor VIII Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Human Coagulation Factor VIII Sales by Country (2021–2032)
3.8.3 Middle East and Africa Human Coagulation Factor VIII Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Coagulation Factor VIII Sales by Type (2021–2032)
4.1.1 Global Human Coagulation Factor VIII Sales by Type (2021–2026)
4.1.2 Global Human Coagulation Factor VIII Sales by Type (2027–2032)
4.1.3 Global Human Coagulation Factor VIII Sales Market Share by Type (2021–2032)
4.2 Global Human Coagulation Factor VIII Revenue by Type (2021–2032)
4.2.1 Global Human Coagulation Factor VIII Revenue by Type (2021–2026)
4.2.2 Global Human Coagulation Factor VIII Revenue by Type (2027–2032)
4.2.3 Global Human Coagulation Factor VIII Revenue Market Share by Type (2021–2032)
4.3 Global Human Coagulation Factor VIII Price by Type (2021–2032)
5 Segment by Application
5.1 Global Human Coagulation Factor VIII Sales by Application (2021–2032)
5.1.1 Global Human Coagulation Factor VIII Sales by Application (2021–2026)
5.1.2 Global Human Coagulation Factor VIII Sales by Application (2027–2032)
5.1.3 Global Human Coagulation Factor VIII Sales Market Share by Application (2021–2032)
5.2 Global Human Coagulation Factor VIII Revenue by Application (2021–2032)
5.2.1 Global Human Coagulation Factor VIII Revenue by Application (2021–2026)
5.2.2 Global Human Coagulation Factor VIII Revenue by Application (2027–2032)
5.2.3 Global Human Coagulation Factor VIII Revenue Market Share by Application (2021–2032)
5.3 Global Human Coagulation Factor VIII Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Company Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Takeda Human Coagulation Factor VIII Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Human Coagulation Factor VIII Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 CSL
6.3.1 CSL Company Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 CSL Human Coagulation Factor VIII Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Human Coagulation Factor VIII Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Grifols
6.5.1 Grifols Company Information
6.5.2 Grifols Description and Business Overview
6.5.3 Grifols Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Grifols Human Coagulation Factor VIII Product Portfolio
6.5.5 Grifols Recent Developments/Updates
6.6 Biogen
6.6.1 Biogen Company Information
6.6.2 Biogen Description and Business Overview
6.6.3 Biogen Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Biogen Human Coagulation Factor VIII Product Portfolio
6.6.5 Biogen Recent Developments/Updates
6.7 Octapharma
6.7.1 Octapharma Company Information
6.7.2 Octapharma Description and Business Overview
6.7.3 Octapharma Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Octapharma Human Coagulation Factor VIII Product Portfolio
6.7.5 Octapharma Recent Developments/Updates
6.8 NovoNordisk
6.8.1 NovoNordisk Company Information
6.8.2 NovoNordisk Description and Business Overview
6.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 NovoNordisk Human Coagulation Factor VIII Product Portfolio
6.8.5 NovoNordisk Recent Developments/Updates
6.9 Greencross
6.9.1 Greencross Company Information
6.9.2 Greencross Description and Business Overview
6.9.3 Greencross Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Greencross Human Coagulation Factor VIII Product Portfolio
6.9.5 Greencross Recent Developments/Updates
6.10 Kedrion
6.10.1 Kedrion Company Information
6.10.2 Kedrion Description and Business Overview
6.10.3 Kedrion Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Kedrion Human Coagulation Factor VIII Product Portfolio
6.10.5 Kedrion Recent Developments/Updates
6.11 BPL
6.11.1 BPL Company Information
6.11.2 BPL Description and Business Overview
6.11.3 BPL Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 BPL Human Coagulation Factor VIII Product Portfolio
6.11.5 BPL Recent Developments/Updates
6.12 Hualan Bio
6.12.1 Hualan Bio Company Information
6.12.2 Hualan Bio Description and Business Overview
6.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Hualan Bio Human Coagulation Factor VIII Product Portfolio
6.12.5 Hualan Bio Recent Developments/Updates
6.13 RAAS
6.13.1 RAAS Company Information
6.13.2 RAAS Description and Business Overview
6.13.3 RAAS Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 RAAS Human Coagulation Factor VIII Product Portfolio
6.13.5 RAAS Recent Developments/Updates
6.14 SinoCellTech
6.14.1 SinoCellTech Company Information
6.14.2 SinoCellTech Description and Business Overview
6.14.3 SinoCellTech Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 SinoCellTech Human Coagulation Factor VIII Product Portfolio
6.14.5 SinoCellTech Recent Developments/Updates
6.15 Taibang Bio
6.15.1 Taibang Bio Company Information
6.15.2 Taibang Bio Description and Business Overview
6.15.3 Taibang Bio Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Taibang Bio Human Coagulation Factor VIII Product Portfolio
6.15.5 Taibang Bio Recent Developments/Updates
6.16 Huarun Boya
6.16.1 Huarun Boya Company Information
6.16.2 Huarun Boya Description and Business Overview
6.16.3 Huarun Boya Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Huarun Boya Human Coagulation Factor VIII Product Portfolio
6.16.5 Huarun Boya Recent Developments/Updates
6.17 Shuanglin Bio
6.17.1 Shuanglin Bio Company Information
6.17.2 Shuanglin Bio Description and Business Overview
6.17.3 Shuanglin Bio Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Shuanglin Bio Human Coagulation Factor VIII Product Portfolio
6.17.5 Shuanglin Bio Recent Developments/Updates
6.18 Yuandashuyang
6.18.1 Yuandashuyang Company Information
6.18.2 Yuandashuyang Description and Business Overview
6.18.3 Yuandashuyang Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Yuandashuyang Human Coagulation Factor VIII Product Portfolio
6.18.5 Yuandashuyang Recent Developments/Updates
6.19 Weiguang Bio
6.19.1 Weiguang Bio Company Information
6.19.2 Weiguang Bio Description and Business Overview
6.19.3 Weiguang Bio Human Coagulation Factor VIII Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Weiguang Bio Human Coagulation Factor VIII Product Portfolio
6.19.5 Weiguang Bio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Coagulation Factor VIII Industry Chain Analysis
7.2 Human Coagulation Factor VIII Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Coagulation Factor VIII Production Mode & Process Analysis
7.4 Human Coagulation Factor VIII Sales and Marketing
7.4.1 Human Coagulation Factor VIII Sales Channels
7.4.2 Human Coagulation Factor VIII Distributors
7.5 Human Coagulation Factor VIII Customer Analysis
8 Human Coagulation Factor VIII Market Dynamics
8.1 Human Coagulation Factor VIII Industry Trends
8.2 Human Coagulation Factor VIII Market Drivers
8.3 Human Coagulation Factor VIII Market Challenges
8.4 Human Coagulation Factor VIII Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Human Coagulation Factor VIII Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Human Coagulation Factor VIII Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Human Coagulation Factor VIII Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Human Coagulation Factor VIII Sales (K Bottles) of Key Manufacturers (2021–2026)
 Table 5. Global Human Coagulation Factor VIII Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Human Coagulation Factor VIII Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Human Coagulation Factor VIII Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Human Coagulation Factor VIII Average Price (USD/Bottle) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Human Coagulation Factor VIII, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Human Coagulation Factor VIII, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Human Coagulation Factor VIII, Product Types and Applications
 Table 12. Global Key Manufacturers of Human Coagulation Factor VIII, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Coagulation Factor VIII Companies by Tier (Tier 1, Tier 2, Tier 3), based on Human Coagulation Factor VIII Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Coagulation Factor VIII Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Human Coagulation Factor VIII Sales by Region (K Bottles), 2021–2026
 Table 18. Global Human Coagulation Factor VIII Sales Market Share by Region (2021–2026)
 Table 19. Global Human Coagulation Factor VIII Sales by Region (K Bottles), 2027–2032
 Table 20. Global Human Coagulation Factor VIII Sales Market Share by Region (2027–2032)
 Table 21. Global Human Coagulation Factor VIII Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Human Coagulation Factor VIII Revenue Market Share by Region (2021–2026)
 Table 23. Global Human Coagulation Factor VIII Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Human Coagulation Factor VIII Revenue Market Share by Region (2027–2032)
 Table 25. North America Human Coagulation Factor VIII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Human Coagulation Factor VIII Sales by Country (K Bottles), 2021–2026
 Table 27. North America Human Coagulation Factor VIII Sales by Country (K Bottles), 2027–2032
 Table 28. North America Human Coagulation Factor VIII Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Human Coagulation Factor VIII Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Human Coagulation Factor VIII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Human Coagulation Factor VIII Sales by Country (K Bottles), 2021–2026
 Table 32. Europe Human Coagulation Factor VIII Sales by Country (K Bottles), 2027–2032
 Table 33. Europe Human Coagulation Factor VIII Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Human Coagulation Factor VIII Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Human Coagulation Factor VIII Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Human Coagulation Factor VIII Sales by Region (K Bottles), 2021–2026
 Table 37. Asia Pacific Human Coagulation Factor VIII Sales by Region (K Bottles), 2027–2032
 Table 38. Asia Pacific Human Coagulation Factor VIII Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Human Coagulation Factor VIII Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Human Coagulation Factor VIII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Human Coagulation Factor VIII Sales by Country (K Bottles), 2021–2026
 Table 42. Latin America Human Coagulation Factor VIII Sales by Country (K Bottles), 2027–2032
 Table 43. Latin America Human Coagulation Factor VIII Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Human Coagulation Factor VIII Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Human Coagulation Factor VIII Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Human Coagulation Factor VIII Sales by Country (K Bottles), 2021–2026
 Table 47. Middle East and Africa Human Coagulation Factor VIII Sales by Country (K Bottles), 2027–2032
 Table 48. Middle East and Africa Human Coagulation Factor VIII Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Human Coagulation Factor VIII Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Human Coagulation Factor VIII Sales (K Bottles) by Type (2021–2026)
 Table 51. Global Human Coagulation Factor VIII Sales (K Bottles) by Type (2027–2032)
 Table 52. Global Human Coagulation Factor VIII Sales Market Share by Type (2021–2026)
 Table 53. Global Human Coagulation Factor VIII Sales Market Share by Type (2027–2032)
 Table 54. Global Human Coagulation Factor VIII Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Human Coagulation Factor VIII Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Human Coagulation Factor VIII Revenue Market Share by Type (2021–2026)
 Table 57. Global Human Coagulation Factor VIII Revenue Market Share by Type (2027–2032)
 Table 58. Global Human Coagulation Factor VIII Price (USD/Bottle) by Type (2021–2026)
 Table 59. Global Human Coagulation Factor VIII Price (USD/Bottle) by Type (2027–2032)
 Table 60. Global Human Coagulation Factor VIII Sales (K Bottles) by Application (2021–2026)
 Table 61. Global Human Coagulation Factor VIII Sales (K Bottles) by Application (2027–2032)
 Table 62. Global Human Coagulation Factor VIII Sales Market Share by Application (2021–2026)
 Table 63. Global Human Coagulation Factor VIII Sales Market Share by Application (2027–2032)
 Table 64. Global Human Coagulation Factor VIII Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Human Coagulation Factor VIII Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Human Coagulation Factor VIII Revenue Market Share by Application (2021–2026)
 Table 67. Global Human Coagulation Factor VIII Revenue Market Share by Application (2027–2032)
 Table 68. Global Human Coagulation Factor VIII Price (USD/Bottle) by Application (2021–2026)
 Table 69. Global Human Coagulation Factor VIII Price (USD/Bottle) by Application (2027–2032)
 Table 70. Takeda Company Information
 Table 71. Takeda Description and Business Overview
 Table 72. Takeda Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 73. Takeda Human Coagulation Factor VIII Product
 Table 74. Takeda Recent Developments/Updates
 Table 75. Bayer Company Information
 Table 76. Bayer Description and Business Overview
 Table 77. Bayer Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 78. Bayer Human Coagulation Factor VIII Product
 Table 79. Bayer Recent Developments/Updates
 Table 80. CSL Company Information
 Table 81. CSL Description and Business Overview
 Table 82. CSL Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 83. CSL Human Coagulation Factor VIII Product
 Table 84. CSL Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 88. Pfizer Human Coagulation Factor VIII Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Grifols Company Information
 Table 91. Grifols Description and Business Overview
 Table 92. Grifols Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 93. Grifols Human Coagulation Factor VIII Product
 Table 94. Grifols Recent Developments/Updates
 Table 95. Biogen Company Information
 Table 96. Biogen Description and Business Overview
 Table 97. Biogen Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 98. Biogen Human Coagulation Factor VIII Product
 Table 99. Biogen Recent Developments/Updates
 Table 100. Octapharma Company Information
 Table 101. Octapharma Description and Business Overview
 Table 102. Octapharma Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 103. Octapharma Human Coagulation Factor VIII Product
 Table 104. Octapharma Recent Developments/Updates
 Table 105. NovoNordisk Company Information
 Table 106. NovoNordisk Description and Business Overview
 Table 107. NovoNordisk Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 108. NovoNordisk Human Coagulation Factor VIII Product
 Table 109. NovoNordisk Recent Developments/Updates
 Table 110. Greencross Company Information
 Table 111. Greencross Description and Business Overview
 Table 112. Greencross Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 113. Greencross Human Coagulation Factor VIII Product
 Table 114. Greencross Recent Developments/Updates
 Table 115. Kedrion Company Information
 Table 116. Kedrion Description and Business Overview
 Table 117. Kedrion Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 118. Kedrion Human Coagulation Factor VIII Product
 Table 119. Kedrion Recent Developments/Updates
 Table 120. BPL Company Information
 Table 121. BPL Description and Business Overview
 Table 122. BPL Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 123. BPL Human Coagulation Factor VIII Product
 Table 124. BPL Recent Developments/Updates
 Table 125. Hualan Bio Company Information
 Table 126. Hualan Bio Description and Business Overview
 Table 127. Hualan Bio Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 128. Hualan Bio Human Coagulation Factor VIII Product
 Table 129. Hualan Bio Recent Developments/Updates
 Table 130. RAAS Company Information
 Table 131. RAAS Description and Business Overview
 Table 132. RAAS Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 133. RAAS Human Coagulation Factor VIII Product
 Table 134. RAAS Recent Developments/Updates
 Table 135. SinoCellTech Company Information
 Table 136. SinoCellTech Description and Business Overview
 Table 137. SinoCellTech Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 138. SinoCellTech Human Coagulation Factor VIII Product
 Table 139. SinoCellTech Recent Developments/Updates
 Table 140. Taibang Bio Company Information
 Table 141. Taibang Bio Description and Business Overview
 Table 142. Taibang Bio Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 143. Taibang Bio Human Coagulation Factor VIII Product
 Table 144. Taibang Bio Recent Developments/Updates
 Table 145. Huarun Boya Company Information
 Table 146. Huarun Boya Description and Business Overview
 Table 147. Huarun Boya Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 148. Huarun Boya Human Coagulation Factor VIII Product
 Table 149. Huarun Boya Recent Developments/Updates
 Table 150. Shuanglin Bio Company Information
 Table 151. Shuanglin Bio Description and Business Overview
 Table 152. Shuanglin Bio Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 153. Shuanglin Bio Human Coagulation Factor VIII Product
 Table 154. Shuanglin Bio Recent Developments/Updates
 Table 155. Yuandashuyang Company Information
 Table 156. Yuandashuyang Description and Business Overview
 Table 157. Yuandashuyang Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 158. Yuandashuyang Human Coagulation Factor VIII Product
 Table 159. Yuandashuyang Recent Developments/Updates
 Table 160. Weiguang Bio Company Information
 Table 161. Weiguang Bio Description and Business Overview
 Table 162. Weiguang Bio Human Coagulation Factor VIII Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle), and Gross Margin (2021–2026)
 Table 163. Weiguang Bio Human Coagulation Factor VIII Product
 Table 164. Weiguang Bio Recent Developments/Updates
 Table 165. Key Raw Materials Lists
 Table 166. Raw Materials Key Suppliers Lists
 Table 167. Human Coagulation Factor VIII Distributors List
 Table 168. Human Coagulation Factor VIII Customers List
 Table 169. Human Coagulation Factor VIII Market Trends
 Table 170. Human Coagulation Factor VIII Market Drivers
 Table 171. Human Coagulation Factor VIII Market Challenges
 Table 172. Human Coagulation Factor VIII Market Restraints
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Coagulation Factor VIII
 Figure 2. Global Human Coagulation Factor VIII Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Human Coagulation Factor VIII Market Share by Type: 2025 & 2032
 Figure 4. Recombinant Factor VIII Product Picture
 Figure 5. Plasma-derived Factor VIII Product Picture
 Figure 6. Global Human Coagulation Factor VIII Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Human Coagulation Factor VIII Market Share by Application: 2025 & 2032
 Figure 8. Hemophilia A
 Figure 9. Spontanous / Trauma
 Figure 10. Surgical
 Figure 11. Other
 Figure 12. Global Human Coagulation Factor VIII Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Human Coagulation Factor VIII Market Size (US$ Million), 2021–2032
 Figure 14. Global Human Coagulation Factor VIII Sales (K Bottles), 2021–2032
 Figure 15. Global Human Coagulation Factor VIII Average Price (USD/Bottle), 2021–2032
 Figure 16. Human Coagulation Factor VIII Report Years Considered
 Figure 17. Human Coagulation Factor VIII Sales Share by Manufacturers in 2025
 Figure 18. Global Human Coagulation Factor VIII Revenue Share by Manufacturers in 2025
 Figure 19. Top 5 and Top 10 Global Human Coagulation Factor VIII Players: Market Share by Revenue in Human Coagulation Factor VIII in 2025
 Figure 20. Human Coagulation Factor VIII Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 21. Global Human Coagulation Factor VIII Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 22. North America Human Coagulation Factor VIII Sales Market Share by Country (2021–2032)
 Figure 23. North America Human Coagulation Factor VIII Revenue Market Share by Country (2021–2032)
 Figure 24. U.S. Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Canada Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 26. Europe Human Coagulation Factor VIII Sales Market Share by Country (2021–2032)
 Figure 27. Europe Human Coagulation Factor VIII Revenue Market Share by Country (2021–2032)
 Figure 28. Germany Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. France Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. U.K. Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Italy Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Russia Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Asia Pacific Human Coagulation Factor VIII Sales Market Share by Region (2021–2032)
 Figure 34. Asia Pacific Human Coagulation Factor VIII Revenue Market Share by Region (2021–2032)
 Figure 35. China Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Japan Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. South Korea Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. India Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Australia Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Taiwan Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Indonesia Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Thailand Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Malaysia Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Philippines Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Latin America Human Coagulation Factor VIII Sales Market Share by Country (2021–2032)
 Figure 46. Latin America Human Coagulation Factor VIII Revenue Market Share by Country (2021–2032)
 Figure 47. Mexico Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Brazil Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Argentina Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Middle East and Africa Human Coagulation Factor VIII Sales Market Share by Country (2021–2032)
 Figure 51. Middle East and Africa Human Coagulation Factor VIII Revenue Market Share by Country (2021–2032)
 Figure 52. Turkey Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Saudi Arabia Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. U.A.E Human Coagulation Factor VIII Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Global Sales Market Share of Human Coagulation Factor VIII by Type (2021–2032)
 Figure 56. Global Revenue Market Share of Human Coagulation Factor VIII by Type (2021–2032)
 Figure 57. Global Human Coagulation Factor VIII Price (USD/Bottle) by Type (2021–2032)
 Figure 58. Global Sales Market Share of Human Coagulation Factor VIII by Application (2021–2032)
 Figure 59. Global Revenue Market Share of Human Coagulation Factor VIII by Application (2021–2032)
 Figure 60. Global Human Coagulation Factor VIII Price (USD/Bottle) by Application (2021–2032)
 Figure 61. Human Coagulation Factor VIII Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS